2304711-82-6
2304711-82-6
Chemical Structure
Frenlosirsen sodium
Synonym(s): ION-935918 sodium; ION251 sodium
- CAS No.: 2304711-82-6
- Formula:C177H211N63Na15O89P15S15
- Molecular Weight:5935.36
SMILES: [Frenlosirsen (sodium)]
Biological Activity: Frenlosirsen sodium (ION-935918 sodium; ION251 sodium) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen sodium inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen sodium is applicable to myeloma-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Frenlosirsen sodium | 96.46% | Frenlosirsen sodium (ION-935918 sodium; ION251 sodium) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen sodium inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen sodium is applicable to myeloma-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hartman JD, et al. Optimal conditions for quantification of IRF4 mRNA and protein as a correlative biomarker in clinical cancer studies. Journal of translational medicine. 2026 Mar 16;24(1):575. [Content Brief]
- [2]. Tong A A, et al. Abstract CT146: Safety, tolerability and molecular correlates of the IRF4-targeted antisense oligonucleotide frenlosirsen in patients with relapsed/refractory multiple myeloma: A phase 1a dose escalation trial. Cancer Research, 2025, 85(8_Supplement_2): CT146.
Keywords
